Wegovy and Ozempic are both brand names for semaglutide — the same active ingredient — yet they are FDA-approved for different purposes, come in different doses, and carry different price tags. If you or your physician is evaluating these two medications, understanding the distinctions is essential for making the right choice.
The Same Molecule, Different Missions
Both Wegovy and Ozempic are manufactured by Novo Nordisk and contain semaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating. It signals fullness to your brain, slows gastric emptying, and helps regulate blood sugar. Semaglutide mimics this hormone in a long-acting form — a once-weekly injection.
However, the FDA approved each medication for a different indication based on the clinical trials submitted by Novo Nordisk:
Ozempic (semaglutide 0.5 mg / 1 mg / 2 mg)
FDA-approved for type 2 diabetes management. Also reduces cardiovascular risk in adults with type 2 diabetes and heart disease. Weight loss is a documented side effect but not the primary indication.
Wegovy (semaglutide 2.4 mg)
FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Higher dose than Ozempic.
Dosing Differences
This is the most significant pharmacological difference. Ozempic's maximum approved dose for diabetes is 2 mg weekly, while Wegovy is titrated up to 2.4 mg weekly — a higher maintenance dose optimized for weight loss outcomes.
Both medications use a gradual titration schedule — starting low and increasing the dose over several months — to allow the body to adjust and minimize gastrointestinal side effects like nausea. With Wegovy, the titration schedule takes approximately 16–20 weeks to reach the full 2.4 mg dose.
Weight Loss Results: How Do They Compare?
Clinical trial data shows meaningful differences in expected weight loss between the two doses:
The STEP 1 trial for Wegovy (2.4 mg semaglutide) showed an average weight loss of approximately 14.9% of body weight over 68 weeks when combined with lifestyle intervention. For a 200-pound patient, that represents roughly 30 pounds.
Ozempic studies for diabetes (at 1 mg) showed average weight reductions of approximately 6–7% of body weight— meaningful, but substantially less than Wegovy's weight-specific dose.
The higher dose in Wegovy is specifically designed to maximize the appetite-suppressing and metabolic effects of semaglutide for weight loss purposes, which explains the greater efficacy.
Side Effects
Both medications share the same side effect profile, as they contain the same active ingredient. The most common side effects are gastrointestinal:
Because Wegovy uses a higher dose, some patients may experience slightly more pronounced side effects. Slow titration and physician monitoring are essential to managing tolerability.
Rare but serious risks for both include pancreatitis, gallbladder disease, and a theoretical risk of thyroid C-cell tumors (based on animal studies). Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
Cost and Insurance Coverage
Both medications are expensive without insurance. Ozempic typically costs $800–$1,000 per month at retail prices, while Wegovy runs $1,300–$1,500 per month at retail. Insurance coverage varies significantly: Ozempic is more commonly covered for patients with type 2 diabetes, while Wegovy coverage for weight loss remains inconsistent across health plans.
Compounded semaglutide has been an affordability option for some patients when brand-name products are unavailable or cost-prohibitive. However, FDA regulations governing compounded semaglutide have changed as of 2025, affecting compounding eligibility. Your Soboba physician will discuss current medication options and their costs at your consultation.
Which One Is Right for You?
The right choice depends on your health profile and goals. If you have type 2 diabetes and want to improve blood sugar control while losing weight, Ozempic may be appropriate. If your primary goal is weight loss and you meet the BMI criteria, Wegovy is specifically designed for that purpose and has stronger clinical evidence for weight outcomes.
At Soboba Medical Weight Loss, our physicians evaluate your individual situation and help you understand all currently available options. Your first consultation is free. Call us at any of our three Orange County locations to get started.
Sources
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." N Engl J Med. 2021;384(11):989–1002. nejm.org
- U.S. Food and Drug Administration. "FDA Approves WegovyTM (semaglutide) Injection 2.4 mg for Chronic Weight Management in Adults with Obesity or Overweight with at Least One Weight-Related Condition." June 2021. fda.gov
- Ozempic (semaglutide) Prescribing Information. Novo Nordisk. novo-pi.com